Eureka Therapeutics, Novartis, Memorial Sloan Kettering deal

Eureka and Memorial Sloan Kettering Cancer Center granted Novartis exclusive, worldwide rights to develop and commercialize ESK1, a

Read the full 180 word article

User Sign In